Torakochirurgia <br> Antithrombotic prophylaxis in cancer patients undergoing thoracic surgery

Anna Fijałkowska

eISSN: 1897-4252
ISSN: 1731-5530

Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

3/2007
vol. 4

Send email

Copy url:

abstract:

Torakochirurgia
Antithrombotic prophylaxis in cancer patients undergoing thoracic surgery

Anna Fijałkowska

Kardiochirurgia i Torakochirurgia Polska 2007; 4 (3): 273–277

Online publish date: 2007/09/14

View full text Get citation

Cancer patients undergoing surgery have at least twofold increased risk of postoperative deep vein thrombosis and threefold risk of fatal pulmonary embolism compared to those without cancer. The observed rate of venous thromboembolism (VTE) among cancer thoracic surgery patients not receiving prophylaxis was about 20%, whereas use of prophylaxis significantly reduces the rate of VTE. Based on strong evidence from randomized clinical trials, recent American and Polish guidelines recommend for patients undergoing cancer thoracic surgery higher dose of low molecular weight heparin (LMWH) or 3 times daily unfractionated heparin combined with mechanical prophylaxis. As was shown in two clinical trials, prophylaxis with LMWH continued 2-3 weeks after hospital discharge in cancer surgery reduced the risk of late DVT. Post-hospital discharge prophylaxis with LMWH is suggested.

keywords:

Torakochirurgia Antithrombotic prophylaxis in cancer patients undergoing thoracic surgery

Anna Fijałkowska

thromboprophylaxis, thoracic surgery, cancer

Torakochirurgia
Antithrombotic prophylaxis in cancer patients undergoing thoracic surgery